In primary lower grade prostate cancer, Wnt pathway activity was associated with the TMPRSS2:ERG fusion protein, known to be able to activate the Wnt pathway, but in advanced disease Wnt pathway activity was frequently lost, suggesting a tumor-suppressive rather than tumor-promoting role under this condition (Wu et al., 2013). Here, TMPRSS2 is linked to prostate carcinoma.